Managing Orders, Pipeline and Upfront Investment Using Business-Specific KPIs
First written in FY2019. 2 of 4 entries say "Raised", first in FY2021. Latest entry: FY2023.
The whole theme swung hardest in 2021: 1 of 9 companies on the "Worse" side.
0 other companies' latest entry also says "Raised".
- FY2023RaisedAnnual report
「Fiscal year ending June 2023 Fiscal year ending June 2026 Growth rate Revenue ¥1,299.225 million ¥1,650.000 million +27.0% (Advanced R&D Support) ¥1,251.738 million ¥1,400.000 million +11.7% (Healthcare Solutions) ¥47.487 million ¥250.000 million +426.5% Operating profit ¥210.982 million ¥300.000 million +42.2%」
In addition to the existing business-specific KPIs, the Company specified revenue and operating profit targets for the Company and each segment for the fiscal year ending June 2026. - FY2021RaisedAnnual report
「Beginning with the achievement of profitability in the current consolidated fiscal year, the five-year medium-term management plan through the fiscal year ending June 2026 sets the following management targets for the final year, as a milestone on the path toward realizing the Company's corporate philosophy.」
In addition to the existing business-specific KPIs of order value, pipeline progress and upfront investment costs, the Company established company-wide numerical targets for the fiscal year ending June 2026. - FY2020RestatedAnnual report
「Accordingly, order value, a leading indicator of revenue, is treated as an important management KPI. In the Biomarker Business, important management KPIs include accelerating the development of key pipelines, monitoring progress and controlling costs related to upfront investment.」
The Company reconfirmed its business-specific KPIs, emphasizing order value in the Metabolomics Business and pipeline progress and upfront investment costs in the Biomarker Business. - FY2019First statedAnnual report
「It is important to promote awareness and understanding of metabolome analysis technology and develop markets in Japan and overseas. Accordingly, order value, a leading indicator of revenue, is treated as an important management KPI. In the Biomarker Business, important management KPIs include accelerating the development of key pipelines, monitoring progress and controlling costs related to upfront investment.」
The Company specified business-specific management KPIs, emphasizing order value in the Metabolomics Business and pipeline progress and upfront investment costs in the Biomarker Business.